CV Wolfram Dempke SAWO ONCOLOGY LTD

Wolfram C. M. Dempke
MD, PhD, MBA, Professor of Haematology & Oncology
SAWO Director & Chief Medical Officer
born February 20, 1962
Nationality and Native Town: German (Gummersbach)
Languages:
German (native language), English (fluently; oral and written)
French (Level B2), Latin (A-level)
Marital Status: Married, five healthy children
General Education:
1968 – 1972:
Elementary School
1972 – 1981:
High School (A-level Certificate)
1981 – 1982:
Military Service (Air Force)
Academic Education:
1982 – 1988:
Studies of Medicine (University Medical School,
in Essen, Germany)
October 31, 1988:
Certificate as a fully qualified physician
March 15, 1989:
Doctoral Thesis: Awarding the degree
“Medical Doctor” (magna cum laude)
1989 – 1991:
Scholarship at the Imperial Cancer Research Fund
(London, UK); Grant for the project: “Resistance
mechanisms of tumour cells following
fractionated X-irradiation in vitro and in vivo”
1991 – 1996:
Junior House Officier (Internal Medicine,
Cardiology, Gastroenterology, Intensive Care,
Haematology and Oncology)
June 1996:
Fully qualified specialist in Internal Medicine
February 1998:
Fully qualified specialist in Haematology and
Oncology (Appointment as Senior Medical
Oncology Consultant)
April 2000:
Postdoctoral Lecturing Qualification:
“Signal-transduction pathways following Cisplatin
exposure” Awarding the degree “M.D., Ph.D.”
(University of Halle, Germany)
2008 – 2011:
Attending MBA correspondence course (European
University School of Economics, Open University
of Hamburg). Degree: Master of Business
Administration
August 2008:
Appointment as “Professor of Medicine”
(University of Munich, Germany)
Leading Positions held:
1997 – 1998:
Deputy Head of the Haematology Department
(Elisabeth Hospital, Recklinghausen, Germany)
1998 – 2000:
Deputy Head and Acting Respresentative of the
Medical Clinic IV (Haematology and Oncology)
(University of Halle)
2001 – 2002:
Head of the Medical Oncology Department of the
General Hospital Goch (Germany)
2002 – 2005:
Executive Medical Director of the TTG Bochum
(a biotechnology company specialised on the
implementation and financing of new tumour
centers on an outpatient basis)
02/2006 – 04/2007:
Lead Medical Science Manager Oncology at BristolMyers Squibb (Munich, Germany)
05/2007 – 02/2008:
Medical Director Oncology at Bristol-Myers Squibb
(Munich, Germany)
03/2008 – 01/2009:
Head of Gobal Medical Affairs Oncology at
MerckSerono (Darmstadt, Germany).
02/2009 – 05/2011:
Head of department of haematology, oncology
and gastroenterology at the Elbland Clinic Holding
(Rode-wich and Riesa, Saxonia, Germany); 60 beds
plus outpatient department
06/2011 – 09/2014:
Honorary Lecturer of Munich University of Applied
Science and Munich University Medical Oncology
Department and member of the programme
committee (Health Care Management and
Economics); Senior Medical Consultant Oncology.
10/2014 – 04/2016:
Executive Medical Director and Global Clinical
Lead (Global Medical Oncology, AstraZeneca,
Cambridge, UK): Responsible for the global
clinical development in the therapeutic area
of lymphomas, NSCLC and ovarian cancer
(antibodies, TKIs).
05/2016 – 12/2016:
Executive Medical Director (Kyowa Kirin
Pharma-ceutical Development Ltd., Galashiels, UK):
Responsible for the global clinical development
(phase I-III) in the therapeutic area of leukaemias
and lymphomas (antibodies).
Present Positions:
Since 01/2017:
Director, Chief Medical Officer and Founder
SAWO Oncology Ltd, Cambridge
I. Original Papers
01. Dempke W, Nehls P, Wandl U, Soll D, Schmidt CG, Osieka R:
Increased cytotoxicity of 1-(2-chloroethyl)-1-nitroso-3(4-methyl)cyclohexylurea by pretreatment with 0 6-methylguanine in resistant
but not in sensitive human melanoma cells.
J Cancer Res Clin Oncol 113: 387-391 (1987)
02. Dempke WCM:
Chemosensibilisierung von humanen Tumorzellen
gegenüber 1-(2-Chloroethyl)-3(4-methylcyclohexyl)-1-nitrosoharnstoff
(MeCCNU) durch Depletion der 06-Alkylguanin-DNS Alkyltransferase
mit 06-Methylguanin.
Universitätsklinikum der Universität Essen: Inauguraldissertation (1988)
03. Dempke WCM, Shellard SA, Fichtinger-Schepman AMJ, Hill BT:
A lack of significant modulation by aphidicolin glycinate in the formation and
removal of platinum-DNA adducts in two logarithmically-growing tumor cell
lines in vitro.
Carcinogenesis 12: 525-528 (1991)
04. Hill BT, Whelan RDH, Hosking LH, Dempke WCM, Bedford P, Shellard SA:
Differential expression of drug resistance following in vitro exposure
of human tumor cell lines to fractionated X-irradiation.
Cancer Treat Reviews 17 (Suppl A): 21-26 (1990)
05. Dempke WCM, Hosking LK, Shellard SA, Hill BT:
Differential cisplatin responses in human carcinoma cell lines
pre-exposed to fractionated X-irradiation.
Biochem Society Transactions 19: 121 (1991)
06. Hill BT, Dempke WCM, Hosking LK, McLean S, Whelan RDH:
Differential expression of P-glycoprotein and certain other multidrug
resistance characteristics in tumour cells pre-exposed in vitro to either
antitumour drugs or to fractionated X-irradiation.
Proceedings of the Third International Congress on Neo-Adjuvant
Chemotherapy, Paris, France: 323-325 (1991)
07. Dempke WCM, Hosking LK, Hill BT:
Expression of collateral sensitivity to cisplatin, methotrexate
and 5-fluorouracil in a human ovarian carcinoma cell line following exposure
to fractionated X-irradiation in vitro.
Sem Oncol 19 (Suppl 3): 66-72 (1992)
08. Dempke WCM, Shellard SA, Hosking LK, Fichtinger-Schepman AMJ, Hill BT:
Mechanisms associated with the expression of cisplatin resistance
in a human tumor cell line following exposure to fractionated X-irradiation
in vitro.
Carcinogenesis 13: 1209-1215 (1992)
09. Dempke WCM, Whelan RDH, Hill BT:
Expression of resistance to etoposide and vincristine in vitro and in vivo
after in vitro X-irradiation of ovarian tumour cells.
Anti-Cancer Drugs 3: 395-399 (1992)
10. Hill BT, Shellard SA, Hosking LK, Dempke WCM, Fichtinger-Schepman AMJ,
Tone T, Scanlon KJ, Whelan RDH:
Characterization of a cisplatin-resistant human ovarian carcinoma cell line
expressing cross-resistance to 5-fluorouracil but collateral sensitivity
to metho-trexate.
Cancer Res 52: 3110-3118 (1992)
11. Bares R, Dempke W, Handt St, Galonska P, Büll U, Osieka R, Mittermayer Ch:
Somatostatin-Rezeptorszinzigraphie (SRS) bei malignen Lymphomen (ML):
erste Ergebnisse und Vergleich mit Befunden der Computertomographie (CT)
und Positronen-Emissions-Tomographie (PET) mit 18-F-markierter Desoxyglucose (FDG).
Horm Metabol Res (Suppl 27): 56-58 (1993)
12. Dempke W, Gansz Ch, Stockert H, Drost H:
Plasmozytom und HIV-Infektion
Med Klinik 91: 477-478 (1996)
13. Dempke W, Firusian N:
Ungewöhnlicher Verlauf eines Hämangioperizytoms.
Med Klinik 93: 726-728 (1998)
14. Firusian N, Dempke W:
An early phase II study of P-32 chromic phosphate injection therapy
of refractory solid tumors and soliary metastases.
Cancer 85: 980-987 (1999)
15. Grothey A, Voigt W, Schöber C, Müller T, Dempke W, Schmoll HJ:
The role of IGF-I and IGF-I-receptor for cell growth, transformation,
apoptosis, and chemoresistance in solid tumors.
J Cancer Res Clin Oncol 125: 166-173 (1999)
16. Dempke W, Firusian N:
Treatment of malignant pericardial effusion with 32P-colloid.
Br J Cancer 80: 1955-1957 (1999)
17. Schmoll HJ, Büchele T, Grothey A, Dempke W:
Where do we stand with 5-FU?
Sem Oncol 26: 589-605 (1999)
18. Dempke W, Voigt W, Grothey A, Schmoll HJ:
Preferential repair of the N-ras gene in K 562 cells after exposure to cisplatin
Anti-Cancer Drugs 10: 545-549 (1999)
19. Dempke W, Grothey A, Schmoll HJ:
Diagnostik und Therapie des malignen Pleura- und Perikardergusses.
Onkologie 22: 526-529 (1999)
20. Kellner O, Dempke W, Schmoll HJ:
Glucoseinfusionen – eine mögliche effektive Therapieoption bei der
Ifosfamid-induzierten Enzephalopathie.
Deutsche Med Wochenschr 124: 1086-1087 (1999)
21. Dempke W, Behrmann C, Schöber C, Büchele T, Grothey A, Schmoll HJ:
Diagnostisches und therapeutisches Management
der oberen Einflußstauung.
Med Klinik 94: 681-684 (1999)
22. Dempke W, Grothey A, Schmoll HJ:
Optionen der Hochdosis-Chemotherapie
bei fortgeschrittenen gynäkologischen Tumoren.
Gyn 4: 368-375 (1999)
23. Dempke W, von Poblozki A, Kellner O, Wolf HH, Schmoll HJ:
Hämorrhagische Diathese als Erstsymptom eines Magenkarzinoms.
Wiener Med Wochenschr 112: 1053-1058 (2000)
24. Dempke W:
Molekulare Indikatoren der Cisplatin-Resistenz und deren Modulation
in einer Reihe von murinen und humanen Tumorzellinien.
Habilitationsschrift der Medizinischen Fakultät der Martin-Luther-Universität
Halle-Wittenberg (2000), 143 Seiten.
25. Dempke W, Voigt W, Grothey A, Hill BT, Schmoll HJ:
Cisplatin resistance and oncogenes - a review
Anti-Cancer Drugs 11: 225-236 (2000)
26. von Poblozki A, Dempke W, Schmoll HJ:
Carboxypeptidase G2-Rescue bei einer Patientin mit Methotrexat-induziertem
Nierenversagen.
Med Klinik 95: 457-460 (2000)
27. Dempke W, von Poblozki A, Grothey A, Schmoll HJ:
Human hematopoietic growth factors: old lessons and new perspectives.
Anticancer Res 20 (Suppl 6D): 5155-5164 (2000)
28. Kellner O, Voigt W, Schneyer U, Dempke W, Schmoll HJ:
ß-HCG induced hyperthyreosis in germ cell cancer.
Anticancer Res 20 (Suppl 6D): 5135-5138 (2000)
29. Grothey A, Kegel T, Dempke W, Schmoll HJ:
Systemische Therapie des hepatozellulären Karzinoms.
Onkologe 6: 327-335 (2000)
30. Dempke W, Schmoll HJ:
Mögliche neue Indikationen für die Therapie mit Erythropoietin.
Med Klink 96: 467-474 (2001)
31. Dempke W, Rie C, Grothey A, Schmoll HJ:
Cyclooxygenase-2: a novel target for cancer chemotherapy?
J Cancer Res Clin Oncol 127: 411-417 (2001)
32. Jordan K, Behrmann C, Rie C, Bläser F, Dempke W:
Das „Pinch off-Syndrom“:
Management einer ungewöhnlichen Portkomplikation.
Onkologie 7: 438-442 (2001)
33. Grothey A, Dempke W:
Aktueller Stand der Bisphosphonat-Therapie in der Hämato-Onkologie.
Int Praxis 42: 291-299 (2002)
34. Dempke W:
Farnesyltransferase inhibitors – a novel approach in the treatment
of advanced pancreatic carcinomas.
Anticancer Res 23 (Suppl 2A): 813-818 (2003)
35. Rennecke A, Voigt W, Müller T, Frühauf A, Schmoll HJ, Beyer C, Dempke W:
Resistance mechanisms following cisplatin and oxaliplatin treatment
of the human teratocarcinoma cell line 2101EP.
Anticancer Res 25: 1147-1156 (2005)
36. Dempke W:
Preclinical and clinical effects of erythropoietin in the management
of anaemia in patients with non-small cell lung cancer.
Anticancer Res 27: 1745-1758 (2007)
37. Linke R, Dempke W:
Management of imatinib resistant CML patients.
Onkologie 30: 574-580 (2007)
38. Alimi K, Firusian N, Dempke W:
Effects of intralesional 32-P chromic phosphate in refractory patients
with head and neck tumours.
Anticancer Res 27: 2997-3000 (2007)
39. Dempke W:
Antiangiogenese in der Tumortherapie: Neuer Ansatz
mit dem dualen Tyrosinkinase-Inhibitor Brivanib.
Arzneimitteltherapie 26: 246-251 (2008)
40. Dempke W, Heinemann V:
Resistance to EGF-R (erbB1) and VEGF-R modulating agents.
Eur J Cancer 45: 1117-1128 (2009)
41. Dempke W, Suto T, Reck M:
Targeted therapies in NSCLC.
Lung Cancer 67: 257-274 (2010)
42. Dempke W, Zippel R:
Src-Kinase-Inhibitoren in der Tumortherapie.
Med Klinik 105: 711-715 (2010)
43. Eisenmann S, Voigt W, Mueller T, Dempke W:
Sequential X-irradiation induced acquired resistance to oxaliplatin but
increased sensitivity to cisplatin in two human teratoma cell lines in vitro.
Anticancer Res 30: 4471-4476 (2010)
44. Dempke W, Zippel R:
Brivanib, a novel dual VEGF-R2/bFGF-R inhibitor.
Anticancer Res 30: 4477-4484 (2010)
45. Dempke W, Heinemann V:
Ras mutational status is a biomarker for resistance to EGF-R inhibitors in
colorectal carcinomas.
Anticancer Res 30: 4673-4678 (2010)
46. Faussner F, Dempke WCM:
Multiple myeloma: myeloablative therapy with autologous stem cell
support versus chemotherapy. A meta-analysis.
Anticancer Res 32: 2103-2109 (2012)
47. Dempke WCM: Gefitinib in non-small cell lung cancer
– an old lesson new re-visited.
Transl Lung Cancer Res 2: 435-438 (2013)
48. Dempke S, Dempke W: Herausforderung Krebs.
NOVA Heft 1: 6-9 (2014)
49. Dempke WCM: Targeted therapy for NSCLC – a double-edged sword?
Anticancer Res 35: 2503-2512 (2015)
50. Sellmann L, Fenchel K, Dempke WCM: Improved overall survival
following TKI treatment in advanced/metastatic NSCLC
– The Holy Grail for cancer treatment?
Transl Lung Cancer Res 4: 223-227 (2015)
51. Dempke WCM, Edvardsen K, Lu S, Reinmuth N, Reck M, Inoue A: Brain
metastases in NSCLC – are TKIs changing the treatment strategy?
Anticancer Res 35: 5797-5806 (2015)
52. Dempke WCM, Sellmann K, Fenchel K, Edvardsen K:
Immunotherapies for NSCLC: Are we cutting the Gordian helix?
Anticancer Res 35: 5745-5757 (2015)
53. Fenchel K, Sellmann L, Dempke WCM:
Overall survival in NSCLC – what is clinically meaningful?
Trans Lung Cancer Res 5: 115-119 (2016)
54. Fenchel K, Dale SP, Dempke WCM:
Improved overall survival following TKI treatment in NSCLC
– are we making progress?
Transl Lung Cancer Res 5: 373-376 (2016)
56. Dempke WCM, Fenchel K:
Pembrolizumab as first-line therapy for NSCLC – a game changer?
Transl Lung Cancer Res 5: 538-542 (2016)
55. Dempke WCM, Fenchel K, Uchiechowski P, Dale SP:
Second and third generation drugs for immune-oncology
– the more the better?
Eur J Cancer, in press (2017)
II. Published Abstracts
01. Osieka R, Soll D, Dempke W, Schmidt CG:
Collateral sensitivity to methotrexate and leucovorin but not to
methotrexate alone in the presence of pleiotropic drug resistance.
J Cancer Res Clin Oncol 114 (Suppl): S32 (1988)
02. Osieka R, Dempke W, Soll D, Schmidt CG:
Ineffective rescue by folinic acid (FA) from methotrexate (M) induced
cytotoxicity in the presence of the 'mdr' phenotype.
Proc Am Ass Cancer Res 30: 515 (1989)
03. Dempke WCM, Shellard SA, Fichtinger-Schepman AMJ, Hill BT:
Aphidicolin does not inhibit repair of cisplatin-induced DNA damage
in a human ovarian cancer cell line.
Br J Cancer 62: 509 (1990)
04. Dempke WCM, Shellard SA, Fichtinger-Schepman AMJ, Hill BT:
A lack of significant modulation of the formation and removal of
platinum-DNA adducts in logarithmically-growing human ovarian tumor
cell lines in vitro by aphidicolin addition.
Cancer Treat Reviews 17 (Suppl A): 92-93 (1990)
05. Hill BT, Hosking LK, Dempke WCM, Whelan RDH, Shellard SA:
Characterisation of a cisplatin-resistant human ovarian carcinoma
cell line expressing collateral sensitivity to methotrexate.
Proc Am Ass Cancer Res 32: 412 (1991)
06. Dempke WCM, Hosking LK, Fichtinger-Schepman AMJ, Hill BT:
Differential responses to cisplatin and methotrexate in two human
ovarian carcinoma cell lines pre-exposed to fractionated X-irradiation.
Br J Cancer 63 (Suppl 13): 40 (1991)
07. Dempke WCM, Osieka R, Hill BT:
Expression of collateral sensitivities to cisplatin, methotrexate
and 5-fluoro-uracil in a human ovarian carcinoma cell line pre-exposed
in vitro to fractionated X-irradiation.
Proc Am Ass Cancer Res 32: 343 (1991)
08. Hill BT, Hosking LK, Dempke WCM, Shellard SA, McLean S, Whelan RDH:
Differential expression of antitumour drug resistance by tumour cells
after exposure to fractionated X-irradiation in vitro.
Radiat Res (Suppl): 17 (1991)
09. Hill BT, Shellard SA, Dempke WCM:
Differential expression of resistance to cisplatin following in vitro
exposure of human tumour cells to fractionated X-irradiation.
ARR Congress: abstract 223 (1991)
10. Dempke WCM, Fichtinger-Schepman AMJ, Hill BT:
Mechanisms associated with the expression of cisplatin resistance
in a human ovarian tumour cell line following exposure
to fractionated X-irradiation.
J Cancer Res Clin Oncol 117 (Suppl III): 103 (1991)
11. Dempke WCM, Osieka R, Hill BT:
Expression of drug resistance following exposure of a human
tumour cell line to fractionated X-irradiation.
J Cancer Res Clin Oncol 118 (Suppl): R3 (1992)
12. Hill BT, Hosking LK, McLean S, Shellard SA, Dempke WCM, Whelan RDH:
Characterization of the drug-resistant phenotype expressed by tumour
cells following exposure in vitro to fractionated X-irradiation.
J Cancer Res Clin Oncol 117 (Suppl III): 89 (1991)
13. McLean S, Dempke WCM, Hill BT:
P-Glycoprotein overexpression in X-ray-pretreated Chinese hamster ovary
and human ovarian carcinoma cell lines.
Br J Cancer 65 (Suppl): 21 (1992)
14. McLean S, Dempke WCM, Whelan RDH, Hosking LK, Hill BT:
Overexpression of P-glycoprotein in human ovarian carcinoma cells
following exposure to fractionated X-irradiation in vitro.
Proc Am Ass Cancer Res 33: 470 (1992)
15. Bares R, Dempke W, Handt St, Galonska P, Büll U, Osieka R, Mittermayer Ch:
Somatostatin-Rezeptorszinzigraphie (SRS) bei malignen Lmphomen (ML):
erste Ergebnisse und Vergleich mit Befunden der Computertomographie (CT)
und Positronen-Emissions-Tomographie (PET) mit 18-F-markierter
Desoxy-glucose (FDG).
DGN Kongress, Köln 1993
16. Dempke W, Gansz Ch, Stockert H, Drost H:
HIV-Infektion und Plasmozytom - eine Kasuistik.
J Hepatology (Suppl 1): abstract 31 (1993)
17. Voigt W, Grothey A, Müller T, Schmoll HJ, Dempke W:
Gene-specific repair of N-ras gene in human K562 cell line following
exposure to cisplatin (CDDP).
Proc Am Ass Cancer Res 40: 155 (1999)
18. Fibich C, Kegel T, Kellner O, Poblozki A, Grothey A, Dempke W,
Schöber C, Schmoll HJ:
T-ICE with PBSC-support in the treatment of relapsed or refractory
germ-cell tumors (GCT), soft tissue sarcomas (STS) and other solid tumors.
Bone Marrow Transpl 23 (Suppl 3): 19-20 (1999)
19. Dempke W, Kegel T, Voigt W, Grothey A, Schmoll HJ, Firusian N:
Treatment of malignant pericardial effusion with 32P-colloid.
Eur J Cancer 35 (Suppl 4): 95 (1999)
20. Dempke W, Schmoll HJ, Hill BT:
Cisplatin resistance in human tumor cell lines is associated with DNA
polymerase ß expression but not with thymidylate synthase expression.
Eur J Cancer 35 (Suppl 4): 193 (1999)
21. Kegel T, Voigt W, Grothey A, Dempke W, Schmoll HJ:
Potential activity of gemcitabine (GEM), taxotere (TAX) and navelbine
(NAV) in anaplastic thyroid carcinoma.
Eur J Cancer 35 (Suppl 4): 197 (1999)
22. Voigt W, Bulankin T, Müller T, Kegel T, Frühauf A, Grothey A, Dempke W,
Schmoll HJ:
Molecular effects of cisplatin (CDDP) downstream of the formation of
CDDP-adducts in the process of induction of apoptosis in human
testicular carcinoma cell line 2102Ep.
Eur J Cancer 35 (Suppl 4): 195 (1999)
23. Kellner O, Kellner L, Kegel T, Dempke W, Schmoll HJ:
Self-limiting perimyocarditis – a case of transient melphalan-induced
cardio-toxicity.
Onkologie 22 (Suppl 1): 177 (1999)
24. Kellner O, Voigt W, Dempke W, Schmoll HJ:
Glucose infusion – a possible approach in the treatment
of ifosfamide-induced encephalopathy.
Onkologie 22 (Suppl 1): 177 (1999)
25. von Poblozki A, Kellner O, Dempke W, Schmoll HJ:
An unusual course of gastric cancer – a lesson in hemostaseology.
Onkologie 22 (Suppl 1): 125 (1999)
26. Voigt W, Kegel T, Grothey A, Dempke W, Schmoll HJ:
Potential activity of gemcitabine (GEM), taxotere (TAX)
and navelbine (NAV) in anaplastic thyroid carcinoma.
Onkologie 22 (Suppl 1): 222 (1999)
27. Wolf HH, Schöber C, Dempke W, Kellner O, Kegel T, Holzhausen HJ,
Schmoll HJ:
Syngeneic transplantation of hematopoietic stem cells in first partial
remission of low-grade Non-Hodgkin’s lymphoma.
Onkologie 22 (Suppl 1): 214 (1999)
28. Dempke W, Grothey A, Schmoll HJ:
Human hematopoietic growth factors: old lessons and new perspectives.
Anticancer Res 19: 5749 (1999)
29. Kellner O, Schneyer U, Voigt W, Hoang-Vu C, Dempke W, Schmoll HJ:
ß-HCG induced hyperthyreosis in a patient with germ cell cancer
– a case report.
Anticancer Res 19: 5721 (1999)
30. Müller T, Voigt W, Bulankin A, Frühauf A, Kegel T, Grothey A, Dempke W,
Schmoll HJ:
Decreased induction of apoptosis is associated with intrinsic cisplatinresistance in the human testicular teratoma cell line (HTCCL) 1411HP.
Proc Am Ass Cancer Res 41: 783 (2000)
31. Rie C, Fibich C, Dempke W, Grothey A, Wolf HH, Wunderlich D,
Mueller LP, Kellner O, Schmoll HJ:
Sequential high-dose chemotherapy with paclitaxel, ifosfamide,
carboplatin and etoposide (T-ICE) in patients with relapsed
non-seminomatous germ cell cancer.
A phase I study.
Onkologie 23 (Suppl 7): 113 (2000)
32. Müller T, Rie C, Voigt W, Bulankin A, Frühauf A, Dempke W, Grothey A,
Schmoll HJ:
Primary cisplatin-resistance is associated with a higher apoptotic
threshold in a human testicular tumor model.
Onkologie 23 (Suppl 7): 112 (2000)
33. Harba A, Voigt W, Müller T, Simon H, Grothey A, Dempke W, Schmoll HJ:
Primary resistance to cisplatin is associated with resistance to drugs
of other substance classes in human testicular cancer cell lines.
Onkologie 23 (Suppl 7): 112 (2000)
34. Fibich C, Rohrberg R, Sommer H, Dempke W, Schmoll HJ:
Phase I-II study to evaluate safety and efficacy
of mycophenolate-motefil (MMF)-treatment in refractory Evans-syndrome.
Onkologie 23 (Suppl 7): 51 (2000)
35. Rennecke A, Voigt W, Müller T, Frühauf A, Schmoll HJ, Dempke W:
Different resistance mechanisms following cisplatin (CDDP)
and oxaliplatin (OXA) treatment of the human teratoma cell line 2102EP.
Proc Am Assoc Cancer Res 42: 930 (2001)
36. Dempke W, von Poblozki A, Schmoll HJ:
Erythropoietin im Stammzellmanagement.
Onkologie 24 (Suppl 3): 7 (2001)
37. Dempke W:
Farnesyltransferase inhibitors – a novel approach in the treatment
of advanced pancreatic carcinomas.
Anticancer Res 22 (Suppl 1B), 496-497 (2002)
38. Kerner H, Schwarzer R, Dempke W:
Treatment of an extensive malignant melanoma (stage III)
with oxaliplatin and docetaxel.
J Cancer Res Clin Oncol 128 (Suppl 1), 137 (2002)
39. Eisenmann S, Simon H, Mueller T, Schmoll HJ, Dempke W:
Resistance to oxaliplatin but collateral sensitivity to cisplatin
in the human terato-carcinoma cell lines in vitro after fractionated
X-irradiation.
Proc Am Assoc Cancer Res 43: 484 (2002)
40. Dempke W:
Preclinical and clinical effects of erythropoietin in the management
of anaemia in patients with non-small cell lung cancer.
Anticancer Res 25 (Suppl 6D): 4805 (2005)
41. Steudel C, Traukov S, Oelschlägel U, Dempke W, Schaich M, Ehninger G,
Thiede C:
Uniparental disomy in adults acute myeloid leukaemia involves specific
Chromosomes and might be associated with inferior outcome.
Proc Am Assoc Cancer Res 48: 32 (2007)
42. Dempke W, Gunawardena B, Hesselt B, Linke R, Alimi K:
Effects of intralesional 32P in refractory patients
with head and neck tumors.
Proc Am Soc Clin Oncol 25 (Suppl 18): 671 (2007)
43. Gunawardena BA, Schlief S, Dempke W, Winterhalter B:
Compassionate use experience with dasatinib therapy in patients
after imatinib and/or nilotinib failure.
Blood 110: 212B (2007)
44. Dempke W:
Brivanib, a noval dual VEGF-R2/bFGF-R inhibitor.
Anticancer Res 28: 4061-4062 (2008)
45. Dempke W:
Ras mutational status is a biomarker for resistance to EGF-R inhibitors
in colorectal carcinomas.
Anticancer Res 28: 4017-4018 (2008)
46. Eisenmann S, Voigt W, Mueller T, Dempke W:
Sequential X-irradiation induced acquired resistance to oxaliplatin but
increased sensitivity to cisplatin in two human teratoma cell lines in vitro.
Anticancer Res 28: 4066 (2008)
47. Faussner F, Pfirrmann M, Dempke W:
High dose chemotherapy with autologous stem cell transplantation
vs standard dose chemotherapy in multiple myeloma: a metaanalysis.
Blood 116: 1464 (2010)
48. Dempke WCM, Rolinski B, Zippel R:
Ponatinib, a new drug for CML patients harboring the T315I mutation.
Anticancer Res 31: 1966 (2011)
49. Faussner F, Pfirrmann M, Dempke WCM:
Multiple myeloma: myeloablative therapy with autologous stem cell
support versus chemotherapy. A meta-analysis.
Anticancer Res 31: 1969-1970 (2011)
50. Azzarok A, Kellermann S, Kutschka von Rothenfels I, Winkler T, Hirche T,
Dempke WCM:
Primary rectal lymphoma: A satisfactory treatment for an unusual case.
Anticancer Res 31: 1961 (2011)
51. Rolinski B, Gerhartz H, Findeisen R, Pilz C, Dempke W:
Generalized allergic exanthema after topic application
of VEGF inhibitors: Case report and review of the literature.
Anticancer Res 31: 1999 (2011)
III. Books and Book Chapters
01. Dempke WCM, Hill BT, Osieka R:
Zelluläre Grundlagen der Interaktionen zwischen Zytostatika
und ionisierenden Strahlen.
In: Pichelmayr R, Schmoll HJ (Hrsg.)
Aktuelle Therapie gastrointestinaler Tumoren
Springer, Hamburg, Berlin, New York, pp. 418-421 (1992)
02. Hill BT, McLean S, Hosking L, Shellard S, Dempke W, Whelan R:
Characterization of the multiple drug resistance phenotype
expressed by tumour cells following in vitro exposure to fractionated
X-irradiation.
In: Senology. Ioannidou-Mouzaka L, Agantis NJ, Karydas I (ed.)
Elsevier Science Publishers B.V., pp. 389-392 (1992)
03. Bares R, Galonska P, Dempke W, Handt S, Büll U, Osieka R:
Somatostatin receptor scintigraphy in malignant lymphoma.
First results and comparison with glucose metabolism measured
by positron-emission tomography.
In: Somatostatin Receptor Imaging. Bihl H and Dörr U (ed.)
Georg -Thieme-Verlag, Stuttgart, New York, pp. 56-58 (1993)
04. Dempke W: Onkologie kompakt.
Ullstein Medical, Wiesbaden 1998, 208 pages
05. Dempke W: Hämatologie kompakt.
Ullstein Medical, Wiesbaden 1998, 74 pages
06. Dempke W, Wolf HH, Fibich C, Schmoll HJ:
Management der peripheren Blutstammzelltransplantation.
In: Schmoll HJ, Höffken K, Possinger K (Hrsg.)
Kompendium Internistische Onkologie, Bd. 1, 3. Aufl.,
Springer-Verlag, Berlin, pp. 1730-1738 (1999)
07. Dempke W, Schmoll HJ:
Prinzipien des Blutzellersatzes.
In: Schmoll HJ, Höffken K, Possinger K (Hrsg.)
Kompendium Internistische Onkologie, Bd. 1, 3. Aufl.,
Springer-Verlag, Berlin, pp. 1717-1729 (1999)
08. Kellner O, Dempke W, Schmoll HJ:
Zentralvenöse Katheter in der Hämatologie und Onkologie.
In: Schmoll HJ, Höffken K, Possinger K (Hrsg.)
Kompendium Internistische Onkologie, Bd. 1, 3. Aufl.,
Springer-Verlag, Berlin, pp. 1739-1753 (1999)
09. Berdel WE, Schmoll HJ, Büchele T, Dempke W:
Prävention und Therapie von Paravasaten/Extravasaten.
In: Schmoll HJ, Höffken K, Possinger K (Hrsg.)
Kompendium Internistische Onkologie, Bd. 1, 3. Aufl.,
Springer-Verlag, Berlin, pp. 1689-1701 (1999)
10. Grothey A, Kegel T, Dempke W, Schmoll HJ:
Seltene Tumore.
In: Schmoll HJ, Höffken K, Possinger K (Hrsg.)
Kompendium Internistische Onkologie, Bd. 2, 3. Aufl.,
Springer-Verlag, Berlin, pp. 2183-2194 (1999)
11. Pralle H, Dempke W:
Haarzelleukämie.
In: Schmoll HJ, Höffken K, Possinger K (Hrsg.)
Kompendium Internistische Onkologie, Bd. 2, 3. Aufl.,
Springer-Verlag, Berlin, pp. 243-255 (1999)
12. Dempke W, Kegel T, Grothey A, Schmoll HJ:
Primär maligne Tumoren des Herzens.
In: Schmoll HJ, Höffken K, Possinger K (Hrsg.)
Kompendium Internistische Onkologie, Bd. 2, 3. Aufl.,
Springer-Verlag, Berlin, pp. 864-872 (1999)
13. Schöber C, Bokemeyer C, Dempke W:
Kardiovaskuläre Toxizität.
In: Schmoll HJ, Höffken K, Possinger K (Hrsg.)
Kompendium Internistische Onkologie, Bd. 1, 3. Aufl.,
Springer-Verlag, Berlin, pp. 1374-1384 (1999)
14. Schöber C, Dempke W, Schuppert F, Dralle H, Schmoll HJ:
Karzinome der Nebenschilddrüse.
In: Schmoll HJ, Höffken K, Possinger K (Hrsg.)
Kompendium Internistische Onkologie, Bd. 2, 3. Aufl.,
Springer-Verlag, Berlin, pp. 1154-1160 (1999)
15. Schöber C, Dempke W, Schmoll HJ:
Peniskarzinom.
In: Schmoll HJ, Höffken K, Possinger K (Hrsg.)
Kompendium Internistische Onkologie, Bd. 2, 3. Aufl.,
Springer-Verlag, Berlin, pp. 1894-1913 (1999)
16. Büchele T, Grothey A, Dempke W, Schmoll HJ:
Adjuvante und palliative, internistische, onkologische Therapie
des colorectalen Karzinoms.
In: Zielinski C, Jakesz R (Hrsg.)
Onkologie heute: colorectales Carcinom.
Springer-Verlag, Berlin, pp. 41-80 (1999)
17. Dempke W, Schmoll HJ:
Expression of cisplatin resistance in a human ovarian carcinoma cell line
following exposure to fractionated X-irradiation in vitro.
In: Krause A, Cichy W, Zierz S (Hrsg.)
Neonatologie und Onkologie
Martin-Luther-Universität Halle-Wittenberg, Halle/Saale, pp.133-137
(1999)
18. Dempke W (Ed.):
Lehrbuch Hämato-Onkologie.
Huber Verlag, Bern 2006, 682 pages.
19. Dempke W:
Molekulare Therapie in der Hämatologie/Onkologie – Grundlagen,
Prinzipien, Perspektiven.
Uni-Med Verlag, Bremen 2004, 108 pages.
20. Dempke W, Schmoll HJ:
Prinzipien des Blutzellersatzes.
In: Schmoll HJ, Höffken K, Possinger K (Hrsg.)
Kompendium Internistische Onkologie, Bd. 1,
Springer-Verlag, Berlin, 4. Aufl., pp. 1291-1304 (2005)
21. Schmid P, Bokemeyer C, Dempke W:
Kardiovaskuläre Toxizität.
In: Schmoll HJ, Höffken K, Possinger K (Hrsg.)
Kompendium Internistische Onkologie, Bd. 1,
Springer-Verlag, Berlin, 4. Aufl., pp. 1904-1915 (2005)
22. Dempke W, Kegel T, Werdan K:
Tumoren des Herzens.
In: Schmoll HJ, Höffken K, Possinger K (Hrsg.)
Kompendium Internistische Onkologie, Bd. 2,
Springer-Verlag, Berlin, 4. Aufl., 3700-3707 (2005)
23. Dempke W, Alimi K, Gebel M:
Lokal-ablative Therapieverfahren.
In: Schmoll HJ, Höffken K, Possinger K (Hrsg.)
Kompendium Internistische Onkologie, Bd. 1,
Springer-Verlag, Berlin, 4. Aufl., pp. 882-892 (2005)
24. Dempke W (Ed.):
Molekulare Therapie in der Hämatologie/Onkologie – Grundlagen,
Prinzipien, Perspektiven.
Uni-Med Verlag, Bremen, 2. erw. Aufl. 2008, 189 pages.
25. Dempke WCMD, Johnson S, Dale SP.
Mogamulizumab for ATL treatment.
Uni-Med Science, Bremen/Boston/Tokyo, 120 pages, in press.
IV. Memberships
01. Member of the American Society of Clinical Oncology (ASCO)
(since 2006)
02. Member of the American Association of Cancer Research (AACR)
(since 1992)
03. Member of the American Society of Hematology (ASH)
(since 2006)
04. Member of the British Association of Cancer Research (BACR)
(since 1990)
05. Member of the Royal College of Physicians (2016)
06. GMC-certified Haematologist and Oncologist (2016)